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ABSTRACT  
 
In recent years, it has become apparent that coronary microvascular 
dysfunction plays a pivotal pathogenic role in angina pectoris. Functional and 
structural mechanisms can affect the physiological function of the coronary 
microvasculature and lead to myocardial ischemia in people without coronary 
atheromatous disease and also in individuals with obstructive coronary artery 
disease.  Abnormal dilatory responses of the coronary microvessels, coronary 
microvascular spasm and extravascular compressive forces have been 
identified as pathogenic mechanisms in both chronic and acute forms of 
ischemic heart disease. The condition characterized by anginal symptoms and 
evidence of myocardial ischemia triggered by coronary microvascular 
dysfunction, in the absence of obstructive coronary disease, is known as 
“microvascular angina”. The concept of microvascular angina however, may 
extend further to include patients with obstructive coronary artery disease and 
individuals with angina post coronary revascularization or heart transplantation, 
since coronary microvascular dysfunction contributes to myocardial ischemia in 
many such patients. Patients with microvascular angina constitute a sizeable 
proportion of all cases of stable angina undergoing diagnostic coronary 
angiography and of those with persisting angina after successful coronary 
revascularization. Coronary microvascular dysfunction is also often responsible 
for angina in individuals with cardiomyopathy and heart valve disease as well 
as acute coronary syndrome cases such as Takotsubo syndrome and MINOCA 
(myocardial infarction with no obstructive coronary artery disease). Patients 
with stable microvascular angina present typically with effort and/or rest chest 
pain and a reduced coronary flow reserve or microvascular spasm. This 
condition, which affects women and men, can markedly impair quality of life 
and prognosis, and represents a substantial cost burden to healthcare systems 
and individuals alike. In recent years, progress in the diagnosis of myocardial 
ischemia and the use of tests to investigate functional and structural causes for 
a reduced coronary flow reserve and microvascular spasm have allowed the 
identification of an increased number of cases of microvascular angina in 
everyday clinical practice. Although some of the available anti-anginal drugs 
may be helpful, treatment of coronary microvascular dysfunction remains a 
major challenge. The present article discusses the fundamental role that 
coronary microvascular dysfunction plays in the pathogenesis of ischemic heart 
disease, the clinical characteristics of patients presenting with microvascular 
angina, and possible diagnostic and therapeutic strategies. 
Key words: Coronary circulation; Microvascular angina – Coronary 
microvascular dysfunction – Ischemic heart disease – Cardiac imaging 
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INTRODUCTION 
 
The term “angina pectoris”, proposed over two centuries ago, is commonly 
considered to be synonymous with obstructive atherosclerotic epicardial 
coronary artery disease (CAD).  The frequently reported association between 
“angina pectoris” (central chest pain), myocardial ischemia and coronary 
atherosclerosis has reinforced the concept that “anginal” pain and myocardial 
ischemia are almost exclusively caused by obstructive CAD.1 Diagnostic and 
therapeutic strategies for angina pectoris in its two main forms of 
presentation, namely chronic stable angina and acute coronary syndrome 
(ACS), have been and continue to be, based upon the obstructive CAD 
paradigm. Current recommendations in international angina management 
guidelines are informed by the notion that coronary atheromatous plaques are 
the main cause for myocardial ischemia.2-4 Nonetheless, the latest ESC 
guidelines 4 acknowledge the pathogenic role of coronary artery spasm and 
coronary microvascular dysfunction (CMD) in myocardial ischemia and the 
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guidelines for the Diagnosis 
and Management of Patients With Stable Ischemic Heart Disease mention 
that microvascular disease, with vascular reactivity related to abnormalities in 
microvascular and endothelial function, contributes to ischemia to a greater 
extent in women than in men.  
 
Although strategies based on the “classical” pathophysiological concepts are 
useful for the management of a substantial proportion of patients with chronic 
stable angina and the majority of ACS patients, the paradigm that obstructive 
CAD is synonymous with myocardial ischemia needs to be revised, as it is not 
universally applicable to individuals presenting with chronic stable angina 5 or 
to a proportion of ACS patients.6 Indeed, functional mechanisms have been 
documented that can cause myocardial ischemia in the absence of 
obstructive CAD. Epicardial coronary artery spasm, as initially proposed by 
Prinzmetal et al 7 and further documented and characterized by Maseri et al.,8 
are striking examples.  Evidence gathered over the past 30 years has made it 
clear that functional and/or structural mechanisms affecting pre-arterioles, 
arterioles and capillaries, represent yet another major cause for myocardial 
ischemia (Figure 1) in the absence of obstructive CAD 9-13 and can also 
contribute to trigger ischemia in patients with CAD.14 
  
The initial descriptions of angina developing in the absence of CAD gave rise 
to the rather ill-defined concepts of “chest pain with normal coronary arteries” 
or “cardiac syndrome X”.15-17  The term “microvascular angina” (MVA) was 
originally proposed by Cannon and Epstein in 1988 to describe patients with 
normal coronary arteriograms and evidence of myocardial ischemia “caused by 
a disorder of the coronary microvasculature”.16 The term MVA has gained 
acceptance over other denominations to define patients with angina despite 
non-obstructive CAD or with completely normal coronary angiograms. It could 
be argued however - as it will be elaborated throughout the manuscript - that 
the term MVA should be applicable to all forms of angina/ischemia triggered by 
CMD, irrespective of the absence or the presence of CAD, rather than 
restricting the term to conditions characterized by myocardial ischemia in the 
absence of obstructive CAD.  
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Progress in the understanding of MVA was slow, as studies were usually 
underpowered, used either very restrictive inclusion criteria or included rather 
heterogeneous groups of patients. Moreover, tools for the assessment of the 
microcirculation were not available until recently in clinical practice. Probably 
as a result of the above, chest pain with normal coronary arteries was 
considered to be an infrequent condition, often non-cardiac in origin, and with 
a benign prognosis.17 Studies in the past decade, however, have shown that 
angina in the absence of obstructive CAD is more common than initially thought 
5, 18 and also that CMD is associated with myocardial ischemia and adverse 
clinical outcomes.19-21 Importantly, as proposed by Camici and Crea,22 CMD can 
be the underlying pathogenic mechanism in a large proportion of angina cases, 
with and without CAD. (Table 1) CMD may result from functional and/or 
structural abnormalities occurring at the site of the coronary microcirculation 
and the relative roles these mechanisms play may vary across different clinical 
settings and also among patients. The present article discusses the 
fundamental role of CMD in the pathogenesis of ischemic heart disease (IHD), 
the clinical characteristics of patients presenting with microvascular angina, and 
possible diagnostic and therapeutic strategies. We also discuss how CMD can 
lead to chronic stable or acute forms of myocardial ischemia 6, 23-26 and impair 
clinical outcomes. 
 
MYOCARDIAL ISCHEMIA – PATHOPHYSIOLOGY – The role of CMD 
 
Anatomy and physiological responses of the coronary circulation 
The myocardium is an aerobic tissue that requires continuous perfusion with 
oxygenated blood to generate the energy necessary for its contraction. Under 
baseline conditions oxygen extraction from the arterial blood is close to 60-
70% and therefore a rise in myocardial oxygen demand can only be met by an 
appropriate increase in coronary blood flow (CBF). Under physiological 
circumstances the coronary circulation provides an adequate match between 
myocardial oxygen demand and supply.  The coronary arterial system 
comprises three compartments - each with a different function - whose 
anatomical borders cannot be clearly delineated in vivo. (Figure 2)  
The proximal compartment is represented by the epicardial arteries, which 
have a capacitance function and offer little resistance to CBF. These are 
vessels ranging from 5.0 mm to 0.5 mm in diameter that run on the surface of 
the heart before branching off into the myocardium giving rise to intramural 
vessels. Epicardial coronary arteries have a thick wall with three, well 
demarcated layers or tunicae: i- the adventitia that harbors the vasa vasorum 
and nerves; ii- the media, with a circular array of vascular smooth muscle (that 
modulates vessel diameter changes); iii- the intima, on which sits the vascular 
endothelium. The more distal - intramyocardial - branches have thinner walls 
and do not possess vasa vasorum. During systole, the epicardial arteries 
accumulate elastic energy as they increase their blood content up to about 
25%. This elastic energy is - at the onset of diastole - converted into kinetic 
energy that contributes to the prompt reopening of the intramyocardial vessels 
after having been compressed during systole. This mechanism is of particular 
relevance considering that 90% of CBF takes place in diastole.27 
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The intermediate compartment is represented by the pre-arteriolar vessels 
with diameters ranging from approximately 500 μm to 100 μm, and 
characterized by a measurable pressure drop along their length. Their specific 
function is to maintain pressure at the origin of downstream arterioles within a 
narrow range when changes in coronary perfusion pressure and/or flow take 
place. The more proximal vessels (500 to 150 μm in diameter) are more 
responsive to changes in flow, whereas the more distal vessels (150 to 100 
μm) are more sensitive to changes in pressure.28 Functionally, their 
vasomotor actions are not under the direct control of diffusible myocardial 
metabolites.  
The distal compartment is represented by the arterioles, which have 
diameters <100 μm and are characterized by a considerable drop in pressure 
along their path. Arterioles are the site where metabolic regulation of CBF 
takes place, as their tone is influenced by substances produced by the 
surrounding cardiac myocytes.29, 30 
 
Pre-arterioles, arterioles and capillaries constitute the coronary 
microcirculation. Under resting conditions, the tone of the coronary 
microvasculature is high, but rapid changes in arteriolar diameter can take 
place to allow the coronary circulation to promptly increase CBF in response 
to increased myocardial oxygen demand, i.e “functional hyperemia”. This 
initial arteriolar response, driven by the strict cross-talk that exists between 
these vessels and the contracting cardiomyocytes, represents the basis for 
“metabolic vasodilatation”.31 Such a drop in arteriolar resistance, to increase 
CBF, subsequently drives a number of vascular adaptations that involve all 
upstream coronary vessels. Capillaries and venules are also an important 
component of the coronary microcirculation and both structural and functional 
abnormalities at this level -i.e. capillary rarefaction or microembolization- can 
contribute to the development of myocardial ischemia. An in-depth discussion 
of the above mechanisms is beyond the scope of this article. Interested 
readers are referred to recently published review articles.28, 32 
 
The different causes of transient myocardial ischemia  
Myocardial ischemia invariably results from an imbalance between myocardial 
metabolic demand and CBF. Inadequate blood supply can be caused by 
anatomical and/or functional abnormalities in all and each of the 
compartments of the coronary circulation. In addition, extravascular factors, 
such as decreased diastolic time and elevated extravascular pressure 
affecting the coronary microcirculation, can also contribute to the development 
of myocardial ischemia.33 (Figures 1 and 2)  
 
Ischemia caused by abnormalities in the epicardial circulation  
Obstructive CAD - Atheromatous plaques can reduce the lumen of the vessel 
and lead to a progressive reduction of coronary flow reserve (CFR) and 
impaired myocardial perfusion. This mechanism can lead to typical exercise- 
or emotional stress-induced ischemic symptoms and signs, including silent 
ischemia.34  
Coronary artery spasm 7, 8 can cause myocardial ischemia as a result of a 
“primary reduction” of CBF. Characteristically, coronary artery spasm patients  
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present with angina at rest associated with transient ST segment elevation or 
depression, which responds rapidly to the administration of nitrates.35 Spasm 
may occur at the site of an atheromatous plaque and/or in angiographically 
normal vessels.35 Intracoronary ergonovine or acetylcholine (ACh) - used for 
diagnosis - can provoke coronary spasm and reproduce the symptoms and 
ECG changes that occur “spontaneously” in patients with vasospastic 
angina.36-38 
 
Ischemia caused by coronary microvascular dysfunction (CMD) 
  
CMD can lead to myocardial ischemia by 1. impairing the ability of the 
coronary microcirculation to increase CBF in response to an increased 
myocardial oxygen demand, an effect which is equivalent to that exerted by 
flow-limiting epicardial coronary artery stenoses, and/or 2. resulting in 
coronary microvascular spasm. CMD is typically the mechanism underlying 
myocardial ischemia in individuals with angina despite completely normal 
coronary arteriograms - also known as “primary” MVA-9 but it can also trigger 
myocardial ischemia in several other clinical conditions, including systemic 
hypertension, cardiomyopathies and obstructive CAD.22  (Figure 1) 
Indeed, CMD can coexist with epicardial CAD, causing or contributing to 
myocardial ischemia and providing additional prognostic value over and 
above the presence of CAD.20  
Structural and functional abnormalities - CMD can result from structural and/or 
functional alterations of the coronary microvasculature. The relative 
importance of these mechanisms may vary in different clinical conditions and 
patient subsets. CMD due to structural changes of the microvasculature has 
been documented in patients with risk factors for CAD and different 
cardiomyopathies and is due to capillary rarefaction and adverse remodeling 
of intramural coronary arterioles. The latter results from medial wall 
thickening, mainly due to smooth muscle hypertrophy and increased collagen 
deposition, with variable degrees of intimal thickening and a reduced 
wall/lumen ratio.  An important feature here is the diffuse nature of this 
remodeling, which generally affects the coronary microvessels in the whole of 
the ventricle.22 These structural changes can, even in the absence of 
epicardial CAD, induce progressive reductions in CFR mimicking the effects 
of flow limiting stenoses. (Figures 1 and 2). The difference, however, is that 
CFR reduction in patients with CMD rarely follows the “regional” (in the 
territory subtended by the stenotic artery), pattern seen in obstructive CAD 
patients, rather appearing as “patchy” 39 with small areas of ischemic tissue 
interspersed among otherwise normal myocardium, or diffuse, involving most 
of the left ventricle. Functional abnormalities leading to CMD include impaired 
dilatation or excessive coronary microvascular constriction. Impaired 
vasodilatation may be due to abnormalities in endothelium-dependent 
mechanisms (frequently associated with diabetes, obesity, smoking, and other 
cardiovascular risk factors), endothelial-independent mechanisms, or both.12, 
40 Inflammation is another potentially important cause of CMD, as recently 
reviewed by Faccini et al.41 Coronary microvascular spasm, originally 
described by Mohri et al 13 can, similarly to epicardial coronary spasm, cause 
myocardial ischemia in the absence of increased myocardial demand and 
trigger rest angina. Structural and functional abnormalities can coexist in a 
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given individual and may modulate the patient’s ischemic threshold.20 In 
angina patients undergoing acetylcholine testing, Ong et al.38, 42 showed that 
approximately 1 out of 4 of patients had microvascular spasm, characterized 
by ischemic ECG changes without visible changes in the diameter of the 
epicardial coronary arteries. (Figure 3) Arrebola-Moreno et al reported that 
coronary microvascular spasm triggered by intracoronary ACh is associated 
with myocardial perfusion abnormalities, abnormal myocardial contractility and 
- in a proportion of patients - elevation of high sensitivity cardiac troponin 
concentrations.43 
Coronary microvascular ischemia, cardiomyocyte injury and stiffness are also 
likely to play a role in the pathophysiology of heart failure with preserved 
ejection fraction (HFpEF).44, 45 In a recent study in over 200 symptomatic 
patients without overt CAD, Taqueti et al.44 showed that impaired CFR was 
independently associated with diastolic dysfunction and adverse events, 
particularly hospitalization for HFpEF. (Figure 4). 
 
Extravascular mechanisms contributing to CMD and myocardial ischemia 
(Figure 2)  
Increased intramyocardial pressure. During the cardiac cycle the pulsatile 
pattern of CBF follows typical physiologic variations that are influenced by 
changes in intramyocardial and intracavitary pressures.46 As approximately 
90% of CBF occurs in diastole,  CBF is vulnerable to the effect of increased 
extravascular pressure (e.g. in left ventricular hypertrophy) 30 and LV diastolic 
dysfunction such as that caused by increased interstitial and perivascular 
fibrosis.47 CBF is also impaired when arteriolar driving pressure in diastole is 
lower than intracavitary pressure, as seen in patients with severe aortic 
stenosis and in those with flow limiting coronary stenoses. Furthermore, 
increased systolic intramyocardial and intracavitary pressures may negatively 
impact myocardial perfusion, as compression of intramural vessels during 
systole may hinder subendocardial vessels tone restoration in diastole, thus 
impairing diastolic perfusion particularly in the subendocardial layers.48 
Reduced diastolic filling time. As CBF occurs predominantly during diastole, 
diastolic time plays a central role in preserving myocardial perfusion. In the 
normal heart, both subendocardial and subepicardial perfusion are maintained 
even with very short diastolic times, as during intense physical exercise. In 
contrast, when coronary driving pressure is significantly lower than 
intracavitary pressure, as in patients with aortic stenosis, a reduction of 
diastolic time can contribute to a critical impairment of myocardial perfusion.49 
 
Myocardial ischemia in acute coronary syndromes 
Atheromatous plaque related mechanisms- For decades, atheromatous 
plaque rupture with thrombus formation has been considered the main 
pathogenic mechanism underlying acute myocardial ischemia and myocardial 
infarction. Yet, current evidence suggests that a sole focus on plaque rupture 
oversimplifies what is actually a complex clinical syndrome. Coronary artery 
thrombosis due to plaque erosion and leading to ACS/NSTEMI is on the rise 
in the current era of intense lipid lowering treatment. Moreover, in about one 
third of patients ACS can occur in the absence of epicardial coronary artery 
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thrombosis or stenosis. In a recent review article, Crea and Libby 50 
recommended a mechanistic approach to the categorization of ACS 
highlighting the role of plaque erosion, inflammation, epicardial spasm and 
microvascular disease. This approach provides a useful clinical framework for 
triaging patients at risk and tailoring therapy in a more personalized and 
precise manner.50 
 
Coronary microvascular obstruction- Myocardial reperfusion in STEMI may be 
associated with a secondary impairment of the coronary microcirculation 
because of endothelial swelling, microvascular spasm, external compression, 
and distal embolization by plaque debris and platelet-leukocyte aggregates 
resulting in coronary microvascular obstruction (CMVO).39, 40, 51 The latter 
prevents effective reperfusion of the ischemic region, despite successful 
recanalization of the culprit vessel (no-reflow).52 No-reflow can be diagnosed 
during coronary angiography using the Thrombolysis In Myocardial Infarction 
(TIMI) flow grade, TIMI myocardial blush grade, and TIMI frame count.53  
Tissue Edema. Changes in capillary permeability, favoring migration of 
intravascular fluid into the interstitium, can cause myocardial edema and 
contribute to CMD through extravascular compression. Edema results from a 
combination of mechanisms including increased interstitial osmolality and 
vascular permeability, abnormal ionic transport and inflammation.54 Coronary 
microvascular compression favors both intravascular plugging by neutrophil-
platelet aggregates and CMVO. Edema can further impair CBF in the setting 
of ST elevation myocardial infarction (STEMI).47, 48 Non-invasive assessment 
of intramyocardial hemorrhage,55 myocardial edema and CMVO can be 
carried out using T2-based and Inversion Recovery cardiac magnetic 
resonance (CMR) imaging.28  
  
CMD of different types, as described in previous sections of this review, can 
trigger unstable angina, NSTEMI or STEMI (“acute MVA”). In this context, two 
conditions have captured the attention of physicians worldwide, i.e. MINOCA 
(myocardial infarction with no obstructive CAD) and Takotsubo syndrome. 
Both have been reviewed extensively elsewhere 23, 25, 56 and will not be 
discussed in detail here. A recent large study showed that approximately 8% 
of all AMI patients are MINOCA cases.6 Other studies report a prevalence 
ranging from 1% to 14%.9, 57 It is not known, however, what proportion of 
MINOCA cases are due to CMD, as opposed to other mechanisms. 
Regarding Takotsubo syndrome, several authors have suggested that CMD 
and more specifically, coronary microvascular spasm, are likely to be the 
underlying cause in a sizeable number of cases.23, 24, 58 The diagnosis of acute 
MVA requires confirmation that no obstructive CAD is present and also 
documentation of CMD - in the absence of epicardial coronary spasm or acute 
coronary thrombosis - as the causal mechanism. The assessment of CMD, 
including microvascular spasm, requires the use of provocative tests with ACh 
or ergonovine during angiography. The high diagnostic yield of these tests, as 
discussed in previous sections of this manuscript, indicates that they should 
be performed routinely as part of the diagnostic pathways for MINOCA and 
Takotsubo syndrome. Recent studies have shown that these tests are safe if 
and when carried out by experienced teams even during the acute phase of 
MINOCA.59, 60 Clinical studies showed impaired outcomes in patients with 
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NSTE-ACS and normal coronary arteries with rates of death or AMI of 1.2% 
and recurrence of unstable symptoms of 8.4% at 1-year follow-up.61 In a more 
recent study in patients with MINOCA the rate of death at 2.5 year follow-up 
was 11.8%.57 The causal mechanism underlying the ACS in these patients 
was not specifically investigated. In relatively small prospective studies 
comparing clinical outcomes in acute versus stable MVA, no major cardiac 
events were observed in either group at a mean follow-up of 36 months.62 
Controversial results have been published regarding acute symptoms or rates 
of hospital re-admission with ACS-MVA.57, 62 In a very recent study in patients 
with MINOCA and documented microvascular spasm, mortality at 3-year 
follow-up was 7.7%.60 
Large, prospective functional studies are needed to clarify the true role of 
CMD in Takotsubo syndrome and MINOCA. 
 
MICROVASCULAR ANGINA  
The term MVA typically describes myocardial ischemia triggered by CMD in 
the absence of CAD.   “Primary” MVA is a term used to describe subjects with 
completely normal coronary arteriograms and no clinically identifiable causes 
for CMD and myocardial ischemia.9 As discussed in previous sections of this 
review, MVA can occur in the presence of conditions such as diabetes 
mellitus, rheumatic diseases, CAD and in subjects with cardiomyopathies and 
heart valve disease, such as aortic stenosis.9 
This section deals with patients who, in the absence of obstructive CAD, have 
stable angina or angina equivalent symptoms and documented myocardial 
ischemia caused by a reduced CFR or microvascular spasm.9, 17, 63 
Prevalence 
Larger numbers of patients than previously thought are now known to have 
angina in the absence of obstructive CAD, with National Cardiovascular Data 
Registry (NCDR) and the WISE (Women’s Ischemic Syndrome Evaluation) 
databases leading to estimations suggesting that in the USA 3 to 4 million 
women and men with symptoms of angina may have no obstructive CAD.18 
Moreover, data from a large USA registry,5 show that over 60% of 398,978 
patients undergoing diagnostic coronary arteriography for the assessment of 
stable angina had normal coronary arteries or non-obstructive CAD (stenoses 
<50%). This is particularly striking given that a large proportion of individuals 
in the study had one or more conventional risk factors for CAD and 69% 
developed transient myocardial ischemia, as assessed by non-invasive 
diagnostic tests. It needs to be mentioned, however, that the occurrence of 
chest pain in the absence of obstructive CAD is not necessarily synonymous 
with MVA. Hence the prevalence of true MVA is likely to be lower than the 
prevalence of ‘angina without obstructive CAD’.   
 
Clinical presentation and diagnosis 
Stable MVA is characterized by effort-induced symptoms similar to those 
observed in patients with angina triggered by obstructive CAD. Very often, 
however, MVA patients have also angina at rest and a variable angina 
threshold, suggestive of dynamic coronary vasomotor changes. Other clinical 
differences that can help identifying patients with MVA include, among others, 
prolonged episodes of chest pain, and a relatively poor response to sublingual 
nitrates in many cases.9, 17, 63, 64  Primary MVA is more common in peri- and 
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post-menopausal women than in men, but the condition should not be 
considered to be one that affects women exclusively. Importantly, both 
atypical chest pain and effort induced dyspnea are common symptoms in 
MVA, particularly in women. In the latter, a history of oophorectomy and 
symptom exacerbation in specific phases of the menstrual cycle as seen in 
some patients should alert physicians as to the presence of MVA. Estrogen 
deficiency has been associated with the development of angina in patients 
with chest pain and angiographically normal coronary arteries.65 In subjects 
with MVA secondary to cardiomyopathies, heart valve disease, and systemic 
diseases, symptoms and signs typical of these conditions are also present.  
 
Diagnostic criteria 
Recently, the Coronary Vasomotor Disorders Study Group (COVADIS) 
proposed the following diagnostic criteria for MVA:66 signs and symptoms of 
myocardial ischemia, reduced CFR (defined as the ratio of CBF during near 
maximal coronary vasodilatation to baseline CBF) or microvascular spasm, 
and documented myocardial ischemia, which is not triggered by obstructive 
CAD, but by functional and/or structural abnormalities at the site of the 
coronary microcirculation. (Table 2). The following represent useful clues for 
the diagnosis of MVA: 
1. Symptoms suggestive of myocardial ischemia. Typical chest pain will alert 
as to the possible ischemic nature of the symptoms, but chest pain can have 
atypical features in MVA patients. The presence of both effort and rest angina 
suggests a possible coexistence of reduced coronary microvascular dilatory 
function and microvascular (and/or epicardial) spasm.64 Angina occurring 
exclusively at rest will point toward epicardial or microvascular spasm as the 
prevailing mechanism.  
2. Absence of obstructive CAD or objective demonstration that CAD is not 
responsible for myocardial ischemia. Excluding angiographic atheroma and/or 
establishing that a stenosis has no effect on coronary physiology, i.e. normal 
fractional flow reserve (FFR) strongly suggests a microvascular origin of 
symptoms.67  
3. Objective documentation of myocardial ischemia. This includes typical ST 
segment changes during chest pain, as assessed by 12-lead ECG exercise 
stress testing or 12-lead Holter monitoring and/or ischemic findings on stress 
echocardiography, single photon emission tomography or CMR perfusion 
scanning. Of note, in a sizeable proportion of MVA patients these imaging 
modalities will give negative results -despite the occurrence of ischemia- 
because, contrary to what is seen in obstructive CAD, myocardial ischemia 
does not follow a regional pattern in MVA and/or ischemia may be in many 
cases limited to the subendocardium.17, 39 
3. Demonstration of coronary microvascular dysfunction. Functional CMD, i.e. 
reduced CFR or microvascular spasm) can be investigated during 
angiography using intracoronary adenosine and ACh. The latter is considered 
to be the gold standard for the assessment of endothelial-dependent coronary 
vasodilatation. Adenosine, a powerful endothelial independent dilator of the 
coronary microcirculation, is used to assess FFR, CFR and the index of 
microcirculatory resistance (IMR) in the catheterization laboratory. CFR 
measurements reflect CBF changes influenced by both the epicardial and 
microvascular compartments and - in the absence of obstructive CAD - CFR 
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is a good marker of CMD. IMR has been suggested to provide good 
reproducible assessment of CMD independently from hemodynamic 
changes.68  An exhaustive description of techniques used to assess CMD is 
beyond the scope of this manuscript. However, recent publications highlight 
the ability of FFR and IMR to more specifically assess epicardial vessel and 
coronary microvascular responses, respectively.69 Moreover, recent data 
suggest that IMR measurements may have prognostic value in both stable 
and ACS patients.70 Noninvasive assessment of CMD can be carried out 
using PET, CMR 69, 71 and pulsed-wave Doppler assessment of CBF on the 
left anterior descending coronary artery.72-76 In 2012, Ong et al 38 reported that 
in patients with effort induced stable angina and non-obstructive CAD 
(approximately 50% of the total study population) intracoronary Ach, at the 
time of diagnostic angiography, triggered distal epicardial spasm or 
microvascular spasm in over 60% of patients. Coronary microvascular spasm, 
however, is a challenging diagnosis, as intracoronary ACh may affect both the 
epicardial vessels and the microvasculature when endothelial dysfunction is 
present thus making it difficult to diagnose microvascular spasm in isolation.  
Ergonovine, an ergot alkaloid acting on serotonin receptors in the coronary 
artery has been also used extensively for the diagnosis of coronary artery 
spasm 77 with results that are similar to those of ACh.36, 37 Both tests have 
been shown to be safe when performed by experienced operators and 
following suitable drug administration protocols.36, 42, 78 
 
Clinical outcomes and economic impact  
Contrary to prior opinion 17, 79 more recent studies have shown that prognosis 
in patients with angina despite the absence of obstructive CAD is not 
necessarily benign.21, 80-82 Both men and women with angina who had 
impaired CFR despite non-obstructive CAD appear - in different series - to 
have worse clinical outcomes.11, 19, 44, 83-87 As recently reviewed by Bairey-
Merz et al,10 almost two thirds of women undergoing clinically indicated 
coronary angiography for suspected CAD in the original cohort of the WISE had 
ischemia with no obstructive CAD11,18. During follow-up, they had a risk rate for 
major adverse cardiac event (death, nonfatal MI, nonfatal stroke, and 
hospitalization for heart failure) exceeding 2.5% yearly by 5 years, as well as 
elevated rates of hospital readmission and repeat angiography. At 10 years,  
cardiovascular death or MI occurred in 6.7% of those with no evident 
angiographic CAD and in 12.8% of those with nonobstructive CAD.88 In the 
WISE database, invasively assessed CFR <2.32 was the best predictor of 
adverse outcomes, with a 5-year MACE rate of 27% versus 9.3% for women 
with a CFR ≥ 2.32 (P=0.01)  Similar outcome findings have been reported 
using non-invasive assessment of CFR with transthoracic echo Doppler or 
PET.19, 86, 89 One of the problems that hampers the assessment of clinical 
outcomes in angina patients without obstructive CAD is that studies have 
used broad and very different inclusion criteria, resulting in heterogeneous 
groups being assessed. Large, prospective studies, in well-characterized 
patients, are required to clarify the natural history of angina without 
obstructive CAD. 
 
In addition to increased rates of adverse cardiovascular events these patients 
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have an impaired quality of life.63, 90  Moreover, they undergo multiple 
diagnostic investigations, a strategy that imposes a substantial financial 
burden on health services. In the U.S and in Europe, healthcare costs related 
to angiography and hospital admission in these individuals are similar to those 
in patients with obstructive CAD.91 Taking all of the above together, it is 
apparent that diagnostic strategies leading to a firm diagnosis of MVA are 
desirable. Albeit not as yet tested in a clinical trial we propose a diagnostic 
algorithm based on our own clinical practice and suggestions by other 
authors, aimed at identifying MVA and characterizing its pathogenic 
mechanisms.92 (FIGURE 5)  
 
 
Management 
The management of MVA represents a major unmet need, as the lack of large 
randomized studies involving homogeneous patient groups makes it difficult to 
generate evidence-based recommendations.  Recent papers have discussed 
the management of patients with ischemia and non-obstructive CAD 10, 92 and 
suggested potential therapies for CMD,10 These recommended therapies, 
however, are not always based on the pathogenesis of MVA, which would be 
desirable.93 This section briefly discusses treatment options taking into 
consideration currently accepted pathogenic mechanisms of CMD and MVA. 
Key objectives of the proposed management strategy are: 1. To improve or 
abolish myocardial ischemia addressing its mechanisms/causes; 2. To 
improve quality of life, and 3. To improve prognosis, identifying and tackling 
mechanisms associated with impaired clinical outcomes.  Targets to be 
addressed include endothelial dysfunction and risk factors, myocardial 
ischemia caused by impaired dilatory ability of the coronary microvessels 
and/or microvascular spasm, and chest pain - increased nociception. 
 
Manage endothelial dysfunction, modifiable cardiovascular risk factors and 
lifestyle. A majority of patients with primary MVA and CMD have endothelial 
dysfunction, and studies using intravascular ultrasound have shown non-
obstructive CAD to be present in a large proportion of patients.94 Aggressive 
management of all modifiable conventional risk factors – hypertension, 
diabetes mellitus, smoking, obesity, sedentary lifestyle, hyperlipidemia, etc - is 
of paramount importance in most MVA patient subgroups.95, 96 Statins - alone 
or in combination with other agents - have been shown to have beneficial 
effects in individuals with coronary endothelial or vascular smooth muscle 
dysfunction despite non-obstructive CAD.97-101 Angiotensin-converting 
enzyme inhibitors (ACE-I) have also been shown to improve exercise 
tolerance and angina symptoms.102, 103 Metformin improves endothelial 
function in patients with MVA without diabetes mellitus.104 The ACC/American 
Heart Association chronic stable angina guidelines 2 recommend the use of 
aspirin in patients with myocardial ischemia and no obstructive CAD, but this 
is not a strong recommendation. 
 
Prevent and treat myocardial ischemia acting on pathogenic mechanisms.  
Robust evidence for the efficacy of antianginal agents in the treatment of MVA 
is lacking at present. Marinescu et al 105 carried out a systematic review of the 
efficacy of current treatment strategies in CMD patients with CFR <2.5, as 
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assessed by PET, CMR imaging, thermodilution methods, or intracoronary 
Doppler. Only eight articles met the strict inclusion criteria established by the 
authors, and a major limitation was the small numbers of patients assessed in 
these studies.  
Calcium channel blockers are likely to represent first line agents for patients 
with documented microvascular spasm and/or abnormal CFR. Despite 
controversial data in small studies,16, 106 expert consensus seems to highlight 
the use of calcium channel blockers as the preferred initial option when 
vasomotor abnormalities, particularly microvascular spasm, are suspected or 
documented. Nitrates do not appear to have major beneficial effects in MVA. 
Less than 50% of patients report improved symptoms with the use of 
sublingual nitroglycerin and a sizeable number have no benefit from oral 
nitrates. Similarly, little if any evidence exists at present for the use of  L–
arginine, the precursor of nitric oxide, to improve CMD.107 Conversely, 
nicorandil, a potassium ATP channel opener with nitrate like actions has been 
reported to have beneficial actions in patients with MVA.108, 109 Fasudil, a rho- 
kinase inhibitor and a potent coronary dilator available in Japan for the 
management of epicardial coronary artery spasm, has also been shown to be 
effective in patients with CMD.110 β-blockers - alone or in combination with 
vasodilators - are useful in MVA patients with predominantly effort induced 
myocardial ischemia in whom a reduction in myocardial oxygen demand may 
increase exercise capacity.9, 111, 112 Caution however is required regarding the 
use of β-blockers (particularly those lacking vasodilating properties) in 
patients with microvascular or epicardial spasm, because these agents may 
increase coronary vasoconstriction by unmasking -adrenoceptors in the 
coronary circulation. Another agent that reduces myocardial oxygen demand 
through its bradycardic effects is ivabradine, but little information exists at 
present regarding the efficacy of this agent in people with MVA. In small pilot 
studies of MVA trimetazidine, a metabolic modulator that shifts cardiac 
metabolism away from fatty acid oxidation improving myocardial metabolism 
during ischemia, was effective to improve symptoms and exercise capacity.113 
Ranolazine, an inhibitor of the late sodium current,114 improved symptoms and 
CFR in women with no obstructive CAD and myocardial ischemia associated 
with CMD.  In other studies, however 115-117– including a randomized trial -117 
ranolazine had no beneficial effects on CMD,116 symptoms or myocardial 
perfusion reserve when all patients were considered, although the subgroup 
of MVA patients with a markedly reduced CFR showed an improved 
response.117 
 
Addressing the problem of abnormal nociception 
As abnormal cardiac nociception may be the main cause for chest pain in 
some patients with MVA,118 tricyclic antidepressants (i.e. imipramine) have 
been proposed for treatment. Acting centrally these agents have modulatory 
effects on norepinephrine uptake and anticholinergic actions that may result in 
analgesia. Imipramine has been shown to improve chest pain in subjects 
without obstructive CAD 119 but side effects requiring discontinuation of the 
drug are common.120
 
In patients defined as “cardiac syndrome X”, xanthine derivatives such as 
aminophylline were suggested to have analgesic effects resulting from 
adenosine receptor blockade. They may also have anti-ischemic actions 
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through attenuation of the coronary microvascular “steal” phenomenon 
reported in MVA patients. Aminophylline improves exercise tolerance and 
exercise induced myocardial ischemia in patients with chest pain despite 
angiographically normal coronaries.121-123  Non pharmacological treatments 
such as spinal cord stimulation, transcutaneous nerve stimulation (TENS), 
enhanced external counter pulsation (EECP), cognitive behavioral therapy 
and other psychological treatments, programmed exercise and cardiac 
rehabilitation have been proposed that can be effective in managing chest 
pain. These, however, have been generally assessed in small size studies 
often involving heterogeneous groups of patients making it difficult to issue 
strong evidence based recommendations at this point in time.   
 
 
 
CORONARY MICROVASCULAR DYSFUNCTION IN PATIENTS WITH 
OBSTRUCTIVE CAD  
Three clinical scenarios have been described where CMD is the underlying 
mechanism of myocardial ischemia, or a major contributor, in patients with 
obstructive CAD. The first is represented by the fact that CFR may be 
abnormal not only in territories subtended by flow limiting stenoses, but also in 
regions supplied by arteries without stenosis,124 suggesting that CMD and 
CAD can coexist and contribute, perhaps synergistically, to the development 
of myocardial ischemia in some individuals. The second relates to persistent 
or recurrent angina after successful PCI and coronary stenting. The third 
relates to CMVO after primary PCI 
 
Evidence of the importance of CMD in patients with CAD has been provided 
by PET studies showing that the inclusion of CFR in risk prediction models 
resulted in more precise re-classification of risk of events at follow up.19   
Furthermore, van de Hoef et al. assessed CFR invasively in non-obstructed 
coronary artery branches in 178 patients with obstructive CAD on diagnostic 
coronary angiography. After multivariable adjustment, CFR ≤ 2.7 was 
associated with a 2.24-fold increase in all-cause mortality hazard.125 Similar 
findings were reported by Gupta et al.126 in 4029 consecutive patients (median 
age 66 years, 50.5% women) with known or suspected CAD who had been 
referred for rest or stress myocardial perfusion positron emission tomography 
scans (Figure 6).  Moreover, in a prospective, multicenter, observational study 
in 4,313 patients with known or suspected CAD, Cortigiani et al. showed that 
CFR ≤2 as assessed by transthoracic Doppler echocardiography, and 
inducible wall motion abnormalities on stress echocardiography were 
independent predictors of mortality. Conversely, normal stress 
echocardiographic results and CFR conferred an annual risk of death <1%.87 
Also, Taqueti et al.127 in a study involving 329 consecutive patients 
undergoing stress testing with myocardial perfusion PET and invasive 
coronary angiography that while global CFR was only modestly associated 
with the overall extent and severity of angiographic disease, a low CFR was 
strongly and independently associated with adverse clinical events. Also of 
interest in this study, only patients with a low CFR appeared to benefit from 
myocardial revascularization using CABG. Taken together these data 
highlight the importance of CMD as a contributor to ischemia, as a marker for 
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risk stratification and as guidance to devise successful treatment strategies in 
patients with obstructive CAD.  
 
Although challenged by a very recent study comparing PCI with a sham 
procedure 128 there is general agreement that PCI has some advantages over 
optimal medical treatment (OMT) regarding symptom control.2, 4  Yet, a 
sizeable proportion of patients continue to experience angina after successful 
myocardial revascularization with PCI 129-133 In the COURAGE trial, 47% of 
patients randomized to PCI had persistent angina at 3-month follow-up, and 
the differences in angina prevalence favoring patients randomized to PCI and 
OMT vs. those randomized to OMT only, decreased over time and became 
non-significant at three years of follow-up.134 Similar findings were observed in 
other prospective trials and meta-analyses. 130-133 Thus, angina post-PCI 
represents an important clinical problem, affecting approximately one fifth to 
50% of patients at 1-year follow-up. Data from the FAME 2 trial, however, 
indicate that when FFR guidance is used to identify flow limiting stenoses the 
rate of residual chest pain after PCI is significantly lower.135 
 
The pathophysiology of angina persisting or recurring after successful PCI is 
complex and involves both structural and functional mechanisms. Structural 
causes of post-PCI angina include in-stent restenosis, stent thrombosis, 
progression of atherosclerotic disease in other coronary segments, 
incomplete revascularization, and diffuse atherosclerosis without focal 
stenosis. Functional causes include vasomotor abnormalities of epicardial 
coronary arteries and/or CMD.  Regarding the latter, Ong et al 42 showed that 
in 51 of 104 patients (49%) undergoing coronary angiography for recurrent 
post-PCI angina despite patent stents, epicardial or microvascular coronary 
spasm, as assessed with ACh provocation, was responsible for the patients’ 
symptoms. Highlighting the role of CMD in post-PCI angina, Li et al.,136 found 
a greater reduction of CBF and a larger IMR increase (intracoronary 
thermodilution method), in patients with post-PCI recurrent angina compared 
to patients without recurrent angina. Similar findings were reported by Milo et 
al.137 using transthoracic Doppler echocardiography of the LAD coronary 
artery. CFR was reduced at 3 and 6 months of follow-up in patients with 
myocardial ischemia on stress testing after successful PCI, but not in those 
with normal stress test responses. It has been suggested that drug eluting 
stent implantation might amplify pre-existing functional abnormalities of the 
coronary circulation.138, 139 
 
In the primary PCI (PPCI) setting, CMVO has been shown to be associated 
with adverse left ventricular remodeling, a higher risk of cardiac death, 
recurrent MI, and heart failure-related re-hospitalization.140, 141  Experimental 
and clinical studies have shown that CMVO is caused by a combination of 
four pathogenic components: ischemic injury, reperfusion injury, distal 
embolization and individual susceptibility to reperfusion injury.40 An individual 
“susceptibility” to microvascular dysfunction, i.e. genetic factors, may 
modulate adenosine-induced vasodilation in this setting. In particular, the 
1976T.C polymorphism of the adenosine 2A receptor gene was found to be 
associated with a higher prevalence of CMVO.51 Further research is needed 
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to gain insight into the molecular mechanisms, pathophysiology, prevention 
and treatment of CMVO. 
 
 
Summary and conclusions 
 
The information reviewed in this manuscript suggests that CMD plays a 
substantial pathogenic role across the spectrum of IHD and indicates that MVA 
caused by CMD can affect large numbers of patients including subjects with no 
obstructive CAD and individuals with obstructive CAD, as well as those with 
persisting angina after anatomically successful coronary recanalization. 
Structural and functional mechanisms affecting the coronary microcirculation 
can lead to myocardial ischemia. Progress in the diagnosis of myocardial 
ischemia and the availability of tests to investigate CFR and coronary 
vasomotion in recent years has allowed a better identification and 
characterization of MVA patients in everyday clinical practice. Clinical outcome 
is not necessarily benign in MVA and efforts should be made to identify these 
individuals at an early stage of their disease. Treatment of the different forms 
of MVA discussed in this manuscript remains a major unmet need, but 
strategies exist that can help improving quality of life. Hopefully, future 
international guidelines on the management of angina will highlight the growing 
importance of CMD and MVA in the field of IHD. 
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